The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are:
* Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment? * What medical problems do participants have when receiving axi-cel treatment?
In this investigator-initiated, single-arm clinical trial, participants will:
* Receive atezolizumab treatment at 2.0×10\^6 cells/Kg as a one-time therapy. * Visit the clinic as instructed for checkups and tests.
Understand and voluntarily sign the informed consent form;
18-70 years of age (inclusive);
Previously untreated CD19-positive large B-cell lymphoma;
Anticipated survival ≥12 weeks;
History of allergy to any of the components of the cell product;
History of stem cell transplantation;
History of organ transplantation;
Presence of active infections;
Single group
Axicabtagene Ciloleucel
Biological/VaccineAxicabtagene Ciloleucel at 2.0×10\^6/Kg
one year PFS
Click on the lead sponsor to view all of their trials.
